SENNA, GIANENRICO
 Distribuzione geografica
Continente #
NA - Nord America 2.614
EU - Europa 2.421
AS - Asia 1.472
AF - Africa 29
SA - Sud America 8
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 3
Totale 6.551
Nazione #
US - Stati Uniti d'America 2.600
CN - Cina 806
SG - Singapore 528
IT - Italia 489
GB - Regno Unito 456
RU - Federazione Russa 363
FR - Francia 272
IE - Irlanda 257
SE - Svezia 245
DE - Germania 165
FI - Finlandia 92
JP - Giappone 29
VN - Vietnam 29
TG - Togo 25
UA - Ucraina 23
HK - Hong Kong 20
BE - Belgio 18
IN - India 15
KR - Corea 11
TR - Turchia 11
CA - Canada 10
ID - Indonesia 9
NL - Olanda 9
AT - Austria 5
CH - Svizzera 5
ES - Italia 4
AR - Argentina 3
CL - Cile 3
LV - Lettonia 3
MX - Messico 3
SA - Arabia Saudita 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AU - Australia 2
BG - Bulgaria 2
CZ - Repubblica Ceca 2
EG - Egitto 2
EU - Europa 2
KG - Kirghizistan 2
LK - Sri Lanka 2
LT - Lituania 2
PE - Perù 2
PL - Polonia 2
SK - Slovacchia (Repubblica Slovacca) 2
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BY - Bielorussia 1
CR - Costa Rica 1
HR - Croazia 1
IL - Israele 1
MA - Marocco 1
MD - Moldavia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PH - Filippine 1
SC - Seychelles 1
TH - Thailandia 1
UZ - Uzbekistan 1
Totale 6.551
Città #
Chandler 626
Singapore 442
Southend 422
Dublin 253
New York 213
Beijing 187
Jacksonville 157
Woodbridge 145
Ashburn 140
Lawrence 109
Princeton 109
Verona 94
Wilmington 90
Houston 76
Ann Arbor 75
Sindelfingen 74
Jinan 60
Shenyang 53
Helsinki 44
Nanjing 38
Redmond 37
Hebei 36
Boardman 27
Bologna 27
Redwood City 27
Lomé 25
Milan 24
Ningbo 24
Changsha 23
Kent 23
Tokyo 23
Guangzhou 21
Haikou 21
Nanchang 21
Norwalk 21
Rome 21
Seattle 21
Tianjin 21
Dong Ket 20
Taizhou 19
Taiyuan 17
Hangzhou 16
Zhengzhou 16
Brussels 15
Dallas 15
Hong Kong 15
Seoul 11
Jiaxing 10
Lanzhou 10
Padova 10
Falls Church 9
Jakarta 9
Los Angeles 9
Moscow 9
Santa Clara 9
Bari 8
Lancaster 8
Amsterdam 7
Boydton 7
Lappeenranta 7
Palermo 7
Chicago 6
Detroit 6
Enterprise 6
Fuzhou 6
Genoa 6
Washington 6
Fairfield 5
Florence 5
Naples 5
Toronto 5
Ancona 4
Arco 4
Brescia 4
Clearwater 4
Delhi 4
Hyderabad 4
Monserrato 4
San Martino Buon Albergo 4
Trecate 4
Treviso 4
Bollate 3
Boston 3
Busto Garolfo 3
Chions 3
Dearborn 3
Dongguan 3
Istanbul 3
Las Vegas 3
London 3
Madrid 3
Negrar 3
Newark 3
Riva 3
Riyadh 3
Santeramo in Colle 3
Texas City 3
Trento 3
Turin 3
Vienna 3
Totale 4.266
Nome #
Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management 199
Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis 109
Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience 96
La salute del respiro: epidemiologia, costi sanitari ed implicazioni sociali delle malattie respiratorie croniche in Europa e in Italia 95
Periostin: The bone and beyond 95
Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and hymenopteria allergy 88
Study on the Immunoreactivity of Triticum monococcum (Einkorn) Wheat in Patients with Wheat-Dependent Exercise-Induced Anaphylaxis for the Production of Hypoallergenic Foods 88
Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels 86
Impatto socio-sanitario e livello del controllo delle patologie respiratorie croniche ostruttive e della rinite in Italia 83
A double-blind placebo-controlled study on the diagnostic accuracy of an electrodermal test in allergic subjects 81
Fatal asthma; is it still an epidemic? 79
Allergy and the bone: unexpected relationships 78
Asthmatic patients in COVID-19 outbreak: Few cases despite many cases 76
Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management 74
Analysis of the positivity rate in IgE positive patients to inhalant allergens in Verona Hospital Laboratory during 2002-2003 74
Scombroid syndrome: it seems to be fish allergy but... it isn't 74
Is hymenoptera venom allergy an occupational disease? 72
Potential benefit of omalizumab in respiratory diseases 70
Wasp venom allergy screening with recombinant allergen testing. Diagnostic performance of rPol d 5 and rVes v 5 for differentiating sensitization to Vespula and Polistes subspecies 70
Allergic rhinitis: pharmacotherapy in pregnancy and old age 70
How much specific is the association between hymenoptera venom allergy and mastocytosis? 70
Omalizumab management beyond clinical trials: the added value of a network model 69
What lies beyond Asthma Control Test: Suggestions for clinical practice 69
Thunderstorm Asthma: A Critical Appraisal Based on Clinical Practice 69
Adverse reaction to local anaesthetics: Is it always allergy? 69
Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity 68
The degree of serological sensitization to cat allergen in patients with or without cat at home 66
COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey 66
Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma 66
SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma 65
Systemic Reactions After Hymenoptera Sting And Raised Serum Tryptase Strongly Suggest Clonal Mast Cells Disorders 63
Asthma control in primary care: the results of an observational cross-sectional study in Italy and Spain 62
Asthma management among different specialists: results from a national Italian survey 62
Low adherence to inhaled corticosteroids/long-acting β2-agonists and biologic treatment in severe asthmatics 62
Biologics for Eosinophilic Granulomatosis with Polyangiitis: one size does not fit all 62
Allergen Immunotherapy Adherence in the Real World: How Bad Is It and How Can It Be Improved? 61
New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic 61
IgE to staphylococcal enterotoxins are undetectable in sera from patients with nasal polyposis 60
Biologic Therapy in a Patient with Asthma and Nasal Polyps 58
Timing of response and long term efficacy of Omalizumab in non-clonal Mast Cell Activation Syndrome: A case series 58
Residual Lung Function Impairment Is Associated with Hyperventilation in Patients Recovered from Hospitalised COVID-19: A Cross-Sectional Study 56
Importance of Cardiopulmonary Exercise Testing amongst Subjects Recovering from COVID-19 56
Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine? 55
COPD prevalence in a north-eastern Italian general population 55
Biologics and global burden of asthma: A worldwide portrait and a call for action 55
Relevance of TH2 markers in the assessment and therapeutic management of severe allergic asthma: A real-life perspective 54
Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase 54
Uncontrolled Asthma: Unmet Needs in the Management of Patients 54
Safety of uSCIT-MPL-4: prevalence and risk factors of systemic reactions in real life 53
How far from correct is the use of adrenaline auto-injectors? A survey in Italian patients 53
Incidence and risk factors for subcutaneous immunotherapy anaphylaxis: the optimization of safety 53
Evaluation of the IgE cross-reactions among vespid venoms. A possible approach for the choice of immunotherapy 52
Component resolved diagnosis (CRD): how much is it presently used by Italian allergists? 52
Evaluation of asthma control in the pharmacy: an Italian cross-sectional study 51
Eosinophilic Granulomatosis With Polyangiitis and Cardiac Involvement: A Case Report 51
Asthma under/misdiagnosis in primary care setting: an observational community-based study in Italy 51
Asthma management among allergists in Italy: results from a survey 51
BCG vaccination and COVID-19: Much ado about nothing? 51
Relationship between hair shedding and systemic inflammation in COVID-19 pneumonia 50
Biologic Therapy in a Patient with Asthma and Nasal Polyps 49
Balancing efficacy against safety in sublingual immunotherapy with inhalant allergens: what is the best approach? 49
Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response 49
ALLERGY AND CORONAVIRUS DISEASE (COVID-19) INTERNATIONAL SURVEY: REAL-LIFE DATA FROM THE ALLERGY COMMUNITY DURING THE PANDEMIC 49
Trends and determinants of Emergency Room admissions for asthma: A retrospective evaluation in Northeast Italy 48
Prevalence and features of asthma-chronic obstructive pulmonary disease overlap in Northern Italy general population 48
The potential role of local pharmacies to assess asthma control: an Italian cross-sectional study 48
Treatment with American Polistes venom was ineffective in an Italian patient allergic to European Polistes 47
Immunoblotting study of specific antibody patterns against latex and banana 47
Targeting eosinophils: severe asthma and beyond 47
Emerging drugs for allergic conjunctivitis 47
Multidisciplinary management in type 2 inflammatory disease 47
Chronic Urticaria Patient Perspective (CUPP): The First Validated Tool for Assessing Quality of Life in Clinical Practice 46
Anaphylaxis and intimate behaviour 46
Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis 45
Orphan immunotherapies for allergic diseases 44
Oral health in asthmatic patients: a review: Asthma and its therapy may impact on oral health 44
Comment on: Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma: reply 44
COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control 44
Clinical response to biologicals for severe asthma: any relevance for sex in different age ranges? 43
Sex in Respiratory and Skin Allergies 43
Biologics for the Treatments of Allergic Conditions 43
Clinical features associated with a doctor-diagnosis of bronchiectasis in the Severe Asthma Network in Italy (SANI) registry 43
Effect of α1 Antitrypsin Deficiency on Lung Volume Decline in Severe Asthmatic Patients Undergoing Biologic Therapy 43
The role of the pharmacy in the management of bronchial asthma: A literature-based evaluation 42
Serum periostin during omalizumab therapy in asthma: A tool for patient selection and treatment evaluation 42
Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy 42
Use of complementary medicine among patients with allergic rhinitis: an Italian nationwide survey. 39
Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI) 39
Who Is Really at Risk for Anaphylaxis Due to COVID-19 Vaccine? 39
One-year mepolizumab for Allergic bronchopulmonary aspergillosis: Focus on steroid sparing effect and markers of response 39
Safety and tolerability of sublingual immunotherapy in clinical trials and real life 37
Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly 37
Respiratory allergies in childhood: Recent advances and future challenges 36
Reconsidering anaphylaxis at the time of COVID-19 pandemic 36
Safety of COVID-19 Vaccines Among the Paediatric Population: Analysis of the European Surveillance Systems and Pivotal Clinical Trials 35
Spontaneous pneumomediastinum complicating severe acute asthma exacerbation in adult patients 35
One year of mepolizumab. Efficacy and safety in real-life in Italy 35
Low‑dose anti‑IL 5 treatment in idiopathic hypereosinophilic syndrome: towards a precision medicine approach for remission maintenance 35
OCCUPATION study (OCCUPationl asthma: a naTIONal based study): a survey on occupational asthma awareness among Italian allergists 34
Hidden Comorbidities in Asthma: A Perspective for a Personalized Approach 33
Totale 5.788
Categoria #
all - tutte 32.062
article - articoli 31.520
book - libri 281
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 261
Totale 64.124


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020359 0 0 0 0 39 48 25 14 14 92 78 49
2020/2021655 78 119 20 92 118 71 17 31 21 8 50 30
2021/2022712 85 172 19 45 16 14 15 48 50 13 51 184
2022/20231.855 139 158 190 266 179 421 31 108 222 15 86 40
2023/20241.347 52 95 121 169 115 283 89 63 20 59 192 89
2024/20251.063 160 182 152 447 122 0 0 0 0 0 0 0
Totale 6.735